Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Dokumenter

  • Morten Møller Poulsen
  • Karen Fjeldborg
  • Marie Juul Ornstrup
  • Thomas Nordstrøm Kjær
  • Nøhr, Mark Klitgaard
  • Steen Bønløkke Pedersen

Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

OriginalsprogEngelsk
TidsskriftB B A - Molecular Basis of Disease
Vol/bind1852
Udgave nummer6
Sider (fra-til)1124-1136
Antal sider13
ISSN0925-4439
DOI
StatusUdgivet - 2015
Eksternt udgivetJa

ID: 195591641